
An experimental ALS therapy is advancing to a 75-person Phase 2 trial in Australia after early findings suggested disease stabilisation and improved function.
The early results came from a small Phase 1/Ib study of NUN-004 and have yet to be confirmed in a larger trial.
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease. It damages the nerve cells controlling movement, progressively affecting the ability to walk, speak, swallow and breathe.
Developed by Australian biotechnology company NuNerve, NUN-004 is a long-acting, protein-based therapy designed to inhibit EphA4, a receptor involved in connections and repair between nerve cells.
The treatment aims to protect motor neurons, the nerve cells responsible for controlling muscle movement, while creating conditions that may allow damaged neural connections to recover.
NuNerve chair and emeritus professor Perry Bartlett, whose research helped establish the scientific basis for the treatment, said the therapy was designed to achieve more than slowing disease progression.
“No approved treatment has been shown to halt or reverse progression across the broad ALS population,” Professor Bartlett said.
“NUN-004 was designed to go further to protect motor neurons and create the conditions for damaged neural connections to repair.
“We have spent more than 25 years following the biology of EphA4, from understanding its role in motor neuron connections to developing a therapy that can now be tested rigorously in people living with ALS.”
The Phase 2 trial will recruit 75 participants across six Australian sites in the Sunshine Coast, Brisbane, Sydney, Newcastle, Melbourne and Perth.
Participants will be randomly assigned in a two-to-one ratio to receive either NUN-004 or a placebo, an inactive treatment, during an initial 24-week blinded study.
A further 24-week open-label phase will allow all participants to receive NUN-004.
Researchers will assess changes in everyday function using the ALS Functional Rating Scale-Revised, alongside measures of safety, breathing, nerve and muscle function, quality of life and biomarkers.
The earlier Phase 1/Ib study involved 20 healthy volunteers and eight people living with ALS.
Although the initial findings suggested possible disease stabilisation and functional improvement, the larger trial will seek to establish whether these early signals represent a genuine treatment effect.
NuNerve’s clinical lead, associate professor Antony Winkel, said the study was designed to put the early findings to a rigorous test.
“People living with ALS urgently need better treatment options grounded in high-quality evidence,” Associate Professor Winkel said.
“This trial combines measures of everyday function with respiratory, neurophysiological and biomarker assessments to determine whether the early Phase 1 signal is a real treatment effect.”
NuNerve was established by the Estate Peter Goodenough Unit Trust and UniQuest to advance more than 25 years of research by Bartlett and emeritus professor Andrew Boyd, originating at the University of Queensland’s Queensland Brain Institute.
The development programme has received three consecutive grants from Australian non-profit organisation FightMND, supporting work from preclinical development through to Phase 2.
NuNerve plans to seek international investment and partnerships to support further development of NUN-004 towards a Phase 3 trial and potential regulatory approval in major markets.









